Author: Akdaş, E.; Öğüt, B.; Erdem, Ö.; Öztaş, M.O.; İlter, N.
Title: Cutaneous reactions following CoronaVac COVIDâ€19 vaccination: a case series of six healthcare workers from a single centre Cord-id: b4doytdp Document date: 2021_8_22
ID: b4doytdp
Snippet: The significant impact of the COVID-19 pandemic on public health, the economy and society required rapid action and the development of vaccines in an unprecedented time frame. While traditional vaccine development may take 15 years or more, vaccine development for SARS-CoV-2 has been reduced to 12-18 months with an accelerated timeline.[1] Phase 1/2 clinical trials of the inactivated vaccine candidate CoronaVac COVID-19 vaccine showed that this vaccine is safe and tolerable, and phase 3 clinical
Document: The significant impact of the COVID-19 pandemic on public health, the economy and society required rapid action and the development of vaccines in an unprecedented time frame. While traditional vaccine development may take 15 years or more, vaccine development for SARS-CoV-2 has been reduced to 12-18 months with an accelerated timeline.[1] Phase 1/2 clinical trials of the inactivated vaccine candidate CoronaVac COVID-19 vaccine showed that this vaccine is safe and tolerable, and phase 3 clinical trials were conducted in Brazil, Turkey and Indonesia.[2] Announced emergency use authorization for CoronaVac on January 13, 2021 in Turkey.[3] Vaccination was initiated primarily in healthcare workers and higher risk groups. The vaccine was given in two doses (days 0 and 28).
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date